Pre-program

THURSDAY March 12

Welcome and introduction

Frédéric LIOTÉ (France), Hang-Korng EA (France), Fernando Perez-Ruiz (Spain)

MORNING - SESSION 1

Keynote introduction: trained immunity and inflammation

Mihai NETEA (The Netherlands)

New insights on epigenetic modulations of IL-1

Musa MHLANGA (The Netherlands)

Coffee break

MORNING - SESSION 2

Multiomics approaches in immune-related diseases

Yang LI (Germany)

Metabolic reprogramming of bone marrow progenitors and atherosclerosis pathophysiology

Hafid AIT-OUFELLA (France)

Poster viewing and networking (session 1)

Lunch break

AFTERNOON - SESSION 1

Repurposing drugs to counteract the pathological responses of chondrocytes to BCP crystals

Tim WELTING (The Netherlands)

Energy metabolism in arterial calcification.

Claudia GOETTSCH (Germany)

Mineralisation in the eyes of people with rare and not-so-rare diseases: What is the overlap between PXE and AMD?

Imre Lengyel (UK)

Oral communications - session 1

Coffee break

AFTERNOON - SESSION 2

Meniscus calcification and calcification formation mechanisms

Jessica BERTRAND (Germany)

Oral communications - session 2

CPP disease and therapeutic perspectives

Augustin LATOURTE (France)

End of the first day

Friday March 13

Welcome & introduction

Hang-Korng EA (France), Tristan PASCART (France)

MORNING - SESSION 1

SGLT-1i, GLP-1RA and hyperuricemia and gout

Chio YOKOSE (USA)

The genetic basis of CPPD disease in 2026

Tony MERRIMAN (New Zealand, USA)

Coffee break

MORNING - SESSION 2

Update on Gut Microbiota in Hyperuricemia and Gout

Robert TERKELTAUB (USA)

Pollutants and gout

Pascal RICHETTE (France)

Oral communications - Session 3

Poster viewing and networking (session 2)

Lunch break

AFTERNOON - SESSION 1

Allopurinol hypersensitivity: how to avoid and how to manage after?

Abhishek ABHISHEK (UK)

Cardiovascular implication of “asymptomatic” hyperuricemia: its it time to change the paradigm?

Claudio BORGHI (Italy)

Coffee break

AFTERNOON - SESSION 2

Oral communications - Session 4

Evidence from New Pragmatic Trials on Treat-to-Target Urate-Lowering Therapy in Gout

Hyon CHOI (USA)

The tophus revisited

Hang-Korng EA (France)

Farewell

Hang-Korng EA (France), Frédéric LIOTÉ (France)

Speakers

ABHISHEK Abhishek (UK)

AIT-OUFELLA Hafid (France)

BERTRAND Jessica (Germany)

BORGHI Claudio (Italy)

CRISAN Tania (Romania)

EA Hang-Korng (France)

GOETTSCH Claudia (Germany)

JOOSTEN Leo (The Netherlands)

KEMPF Hervé (France)

LATOURTE Augustin (France)

LENGYEL Imre (UK)

LI Yang (Germany)

LIOTÉ Frédéric (France)

MERRIMAN Tony (New Zealand)

MHLANGA Musa (The Netherlands)

NASI Sonia (Switzerland)

NETEA Mihai (The Netherlands)

PASCART Tristan (France)

PEREZ-RUIZ Fernando (Spain)

RICHETTE Pascal (France)

SO Alexander (Switzerland)

TERKELTAUB Robert (USA)

WELTING Tim (The Netherlands)

YOKOSE Chio (USA)

Pre-program

THURSDAY March 12

Welcome and introduction

MORNING - SESSION 1

Keynote introduction: trained immunity and inflammation

New insights on epigenetic modulations of IL-1

Coffee break

MORNING - SESSION 2

Multiomics approaches in immune-related diseases

Metabolic reprogramming of bone marrow progenitors and atherosclerosis pathophysiology

Poster viewing and networking (session 1)

Lunch break

AFTERNOON - SESSION 1

Repurposing drugs to counteract the pathological responses of chondrocytes to BCP crystals

Energy metabolism in arterial calcification.

Mineralisation in the eyes of people with rare and not-so-rare diseases: What is the overlap between PXE and AMD?

Oral communications - session 1

Coffee break

AFTERNOON - SESSION 2

Meniscus calcification and calcification formation mechanisms

Oral communications - session 2

CPP disease and therapeutic perspectives

End of the first day

Friday March 13

Welcome & introduction

MORNING - SESSION 1

SGLT-1i, GLP-1RA and hyperuricemia and gout

The genetic basis of CPPD disease in 2026

Coffee break

MORNING - SESSION 2

Update on Gut Microbiota in Hyperuricemia and Gout

Pollutants and gout

Oral communications - Session 3

Poster viewing and networking (session 2)

Lunch break

AFTERNOON - SESSION 1

Allopurinol hypersensitivity: how to avoid and how to manage after?

Cardiovascular implication of “asymptomatic” hyperuricemia: its it time to change the paradigm?

Coffee break

AFTERNOON - SESSION 2

Oral communications - Session 4

Evidence from New Pragmatic Trials on Treat-to-Target Urate-Lowering Therapy in Gout

The tophus revisited

Farewell

Speakers